Abdel G. Babiker
A5106791162- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Statistical Methods in Clinical Trials
- Advanced Causal Inference Techniques
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Topology and Set Theory
- SARS-CoV-2 detection and testing
- Statistical Methods and Bayesian Inference
- Statistical Methods and Inference
- Advanced Banach Space Theory
- HIV-related health complications and treatments
- Global Maternal and Child Health
- Pneumocystis jirovecii pneumonia detection and treatment
- Rings, Modules, and Algebras
- Adolescent and Pediatric Healthcare
- Housing Market and Economics
- Ethics in Clinical Research
- Viral-associated cancers and disorders
- Financial Literacy, Pension, Retirement Analysis
- Child Nutrition and Water Access
- Algebraic structures and combinatorial models
University College London
2015-2024
Medical Research Council
2015-2024
MRC Clinical Trials Unit at UCL
1997-2023
Australian National University
2022
University Medical Center
2020
University of Copenhagen
2020
Rigshospitalet
2020
Gentofte Hospital
2020
Aarhus University Hospital
2020
Baylor University
2020
BackgroundAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral yet shown to be efficacious.MethodsWe conducted a double-blind, randomized, placebo-controlled trial intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence lower respiratory tract infection. Patients randomly assigned receive either (200 mg loading dose on day 1, followed by 100 daily up 9 additional days) or placebo 10 days....
BackgroundLY-CoV555, a neutralizing monoclonal antibody, has been associated with decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients coronavirus disease 2019 (Covid-19). Data are needed on effect this antibody patients who hospitalized Covid-19.MethodsIn platform trial therapeutic agents, we randomly assigned had Covid-19 without end-organ failure 1:1 ratio to receive either LY-CoV555 matching placebo. In addition, all received...
Abstract A case‐control study comprising 216 cases of pancreatic cancer and 279 controls was conducted to investigate the relationship with certain chronic medical conditions consumption tea, coffee alcoholic beverages. Significant positive associations preexisting diabetes mellitus gall‐bladder disease were observed there weak evidence association liver disease. The relative risks for gallstones diagnosed at least one year previously 4.1 ( p = 0.005) 2.8 0.01) respectively. Cases drank...
Untreated human immunodeficiency virus (HIV) infection is characterized by progressive depletion of CD4+ T lymphocyte (CD4) count leading to the development opportunistic diseases (acquired syndrome (AIDS)), and more recent data suggest that HIV also associated with an increased risk serious non-AIDS (SNA) including cardiovascular, renal, liver non-AIDS-defining cancers. Although combination antiretroviral treatment (ART) has resulted in a substantial decrease morbidity mortality persons...
BackgroundSince the 1918 influenza pandemic, non-randomised studies and small clinical trials have suggested that convalescent plasma or anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) might benefit for patients with infection, but definitive data do not exist. We aimed to evaluate safety efficacy of hIVIG in a randomised controlled trial.MethodsThis randomised, double-blind, placebo-controlled trial was planned 45 hospitals Argentina, Australia, Denmark, Greece, Mexico, Spain,...
In a randomized, placebo-controlled, clinical trial, bamlanivimab, SARS-CoV-2-neutralizing monoclonal antibody, given in combination with remdesivir, did not improve outcomes among hospitalized patients COVID-19 based on an early futility assessment.
Background: Levels of plasma SARS-CoV-2 nucleocapsid (N) antigen may be an important biomarker in patients with COVID-19 and enhance our understanding the pathogenesis COVID-19. Objective: To evaluate whether levels can predict short-term clinical outcomes identify viral factors associated hospitalized SARS-CoV-2. Design: Cross-sectional study baseline level from 2540 participants enrolled TICO (Therapeutics for Inpatients With COVID-19) platform trial August 2020 to November 2021,...
In the Strategic Timing of Antiretroviral Treatment (START) study, immediate combination antiretroviral therapy (cART) initiation reduced cancer risk by 64%. We hypothesized that reduction was higher for infection-related and determined differences in CD4 cell counts human immunodeficiency virus (HIV) RNA between study arms. Incident malignancies START were categorized into infection-unrelated cancer. used Cox models to assess factors associated with both categories. sequential adjustment...
Future strategies aiming to achieve HIV-1 remission are likely target individuals with small reservoir size.We retrospectively investigated factors associated DNA levels in European, perinatally HIV-infected children starting antiretroviral therapy (ART) <6 months of age.Total was measured from 51 long-term suppressed aged 6.3 years (median) after initial viral suppression. Factors log10 total were analyzed using linear regression.At ART initiation, median [IQR] 2.3 [1.2-4.1] months, CD4% 37...
In the Fluid Expansion as a Supportive Treatment (FEAST) trial, an unexpectedly high proportion of participants from eastern Uganda presented with blackwater fever (BWF).
BackgroundChildren with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for TB.MethodsWe nested a two-period, fixed-order pharmacokinetic substudy within open-label, multicentre, randomised, controlled, non-inferiority ODYSSEY trial at research centres South Africa, Uganda, Zimbabwe. Children (aged 4 weeks <18 years) TB who were eligible...
Ensovibep (MP0420) is a designed ankyrin repeat protein, novel class of engineered proteins, under investigation as treatment SARS-CoV-2 infection.To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared care alone.Double-blind, randomized, placebo-controlled, trial. (ClinicalTrials.gov: NCT04501978).Multinational, multicenter trial.Adults COVID-19.Intravenous 600 mg, or placebo.Ensovibep was...
For people with HIV and CD4+ counts >500 cells/mm3, early initiation of antiretroviral therapy (ART) reduces serious AIDS non-AIDS (SNA) risk compared deferral treatment until are <350 cells/mm3. Whether excess SNA persists once ART is initiated for those who defer uncertain.The Strategic Timing AntiRetroviral Treatment (START) trial, as previously reported, randomly assigned 4684 ART-naive HIV-positive adults .500 cells/mm3 to immediate after random assignment (n = 2325) or deferred (n=...
Background/aims Safe and effective therapies for COVID-19 are urgently needed. In order to meet this need, the Accelerating Therapeutic Interventions Vaccines public–private partnership initiated Therapeutics Inpatients with COVID-19. is a multi-arm, multi-stage platform master protocol, which facilitates rapid evaluation of safety efficacy novel candidate antiviral therapeutic agents adults hospitalized Five have so far entered answers already provided three these. Other expected enter...
BackgroundIntegrase inhibitor (INSTI) with boosted darunavir (DRV/r), a regimen high-resistance barrier, avoiding NRTI toxicities, might be switching option in children living HIV (CLWHIV).MethodsSMILE is randomised non-inferiority trial evaluating safety and antiviral efficacy of once-daily INSTI + DRV/r vs. continuing on current standard-of-care (SOC) triple ART (2NRTI PI/NNRTI) virologically-suppressed CLWHIV aged 6–18 years. The primary outcome the proportion confirmed HIV-RNA ≥50...
Many cohort studies and clinical trials have designs which involve repeated measurements of disease markers. One problem in such longitudinal studies, when the primary interest is to estimate compare evolution a marker, that planned data are not collected because missing due visits and/or withdrawal or attrition (for example, death). Several methods analyse available, provided at random. However, serious biases can occur ness informative. In cases, one needs apply simultaneously model...
Many cohort studies and clinical trials use repeated measurements of laboratory markers to track disease progression evaluate new therapies. A major problem in the analysis such is that marker data are censored some patients owing withdrawal, loss follow-up, or death. The objective this paper impact selective dropouts attributable death on estimates change among different groups.Data CD4 cell count human immunodeficiency virus 1-infected individuals from a trial study used illustrate...
Non-inferiority trials are increasingly used to evaluate new treatments that expected have secondary advantages over standard of care, but similar efficacy on the primary outcome. When designing a non-inferiority trial with binary outcome, choice effect measure for margin (e.g. risk ratio or difference) has an important sample size calculations; furthermore, if control event observed is markedly different from assumed, can quickly lose power results become difficult interpret.We propose way...
Abstract Many cohort studies and clinical trials are designed to compare rates of change over time in one or more disease markers several groups. One major problem such longitudinal is missing data due patient drop‐out. The bias efficiency six different methods estimate changes with incomplete observations were compared: generalized estimating equation estimates (GEE) proposed by Liang Zeger (1986); unweighted average ordinary least squares (OLSE) individual (UWLS); weighted OLSE (WLS);...